Erratum: Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (Journal of Pharmacology and Experimental Therapeutics (2013) 344 (141-154) DOI: 10.1124/jpet.112.199497);Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 141-154

  McCoy, Alene T ^a   Benoist, Caroline C ^a   Wright, John W ^a   Kawas, Leen H ^a   Bule Ghogare, Jyote M ^a   Zhu, Mingyan ^a   Appleyard, Suzanne M ^a   Wayman, Gary A ^a   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN DERIVATIVE; N HEXANOIC TYROSYLISOLEUCINE (6) AMINOHEXANOIC AMIDE; SCOPOLAMINE; SYNAPSIN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEMENTIA ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DENDRITIC SPINE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; HYDROPHOBICITY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROCOGNITIVE ACTIVITY; PROTEIN LOCALIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

EID: 84871699216     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199497concern     Document Type: Erratum

References (43)

1. Abhold RH and Harding JW (1988) Metabolism of angiotensins II and III by membrane-bound peptidases from rat brain. J Pharmacol Exp Ther 245:171-177.
2. Balschun D, Moechars D, Callaerts-Vegh Z, Vermaercke B, Van Acker N, Andries L, and D'Hooge R (2010) Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning. Cereb Cortex 20: 684-693.
3. Behera D, Damre A, Varghese A, and Addepalli V (2008) In vitro evaluation of hepatic and extra-hepatic metabolism of coumarins using rat subcellular fractions: correlation of in vitro clearance with in vivo data. Drug Metabol Drug Interact 23: 329-350.
4. Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2011) Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J Pharmacol Exp Ther 339:35-44.
5. Braszko JJ, Kupryszewski G, Witczuk B, and Wísniewski K (1988) Angiotensin II- (3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 27: 777 - 783.
6. Calissano P, Matrone C, and Amadoro G (2010) Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Dev Neurobiol 70:372-383.
7. De Bundel D, Smolders I, Vanderheyden P, and Michotte Y (2008) Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci Ther 14:315-339.
8. Dewey AL, Wright JW, Hanesworth JM, and Harding JW (1988) Effects of aminopeptidase inhibition on the half-lives of [125I]angiotensins in the cerebroventricles of the rat. Brain Res 448:369-372.
9. Di L, Kerns EH, Gao N, Li SQ, Huang Y, Bourassa JL, and Huryn DM (2004) Experimental design on single-time-point high-throughput microsomal stability assay. J Pharm Sci 93:1537-1544. (Pubitemid 38725025)
10. Ebens A, Brose K, Leonardo ED, Hanson MG, Jr, Bladt F, Birchmeier C, Barres BA, and Tessier-Lavigne M (1996) Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron 17: 1157-1172. (Pubitemid 27021101)
11. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, and Bredt DS (2000) PSD-95 involvement in maturation of excitatory synapses. Science 290:1364-1368.
12. Faure S, Chapot R, Tallet D, Javellaud J, Achard JM, and Oudart N (2006) Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J Physiol Pharmacol 57:329-342. (Pubitemid 44543870)
13. Ferreira A and Rapoport M (2002) The synapsins: beyond the regulation of neurotransmitter release. Cell Mol Life Sci 59:589-595. (Pubitemid 34457537)
14. Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, and Brandeis R (2003) M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 20:349-356. (Pubitemid 38146993)
15. Gard PR (2004) Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 8:7-14.
16. Gard PR (2008) Cognitive-enhancing effects of angiotensin IV. BMC Neurosci 9 (Suppl 2):S15.
17. Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, and Noguchi J (2010) Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci 33: 121-129.
18. Kato N, Nakanishi K, and Nemoto K (2009) Efficacy of HGF gene transfer for various nervous injuries and disorders. Cent Nerv Syst Agents Med Chem 9:300-306.
19. Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, and Harding JW (2012) Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. J Pharmacol Exp Ther 340:539-548.
20. Kawas LH, Yamamoto BJ, Wright JW, and Harding JW (2011) Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity. J Pharmacol Exp Ther 339:509-518.
21. Kramár EA, Armstrong DL, Ikeda S, Wayner MJ, Harding JW, and Wright JW (2001) The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 897:114-121. (Pubitemid 32244358)
22. Kramár EA, Harding JW, and Wright JW (1997) Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 68:131-138. (Pubitemid 27138368)
23. Krebs LT, Kramár EA, Hanesworth JM, Sardinia MF, Ball AE, Wright JW, and Harding JW (1996) Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pept 67:123-130. (Pubitemid 26392244)
24. Lee J, Albiston AL, Allen AM, Mendelsohn FA, Ping SE, Barrett GL, Murphy M, Morris MJ, McDowall SG, and Chai SY (2004) Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 124:341-349. (Pubitemid 38229654)
25. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, and Gan LS (2006) Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605. (Pubitemid 44285402)
26. Meijering E, Jacob M, Sarria JC, Steiner P, Hirling H, and Unser M (2004) Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 58 :167-176. (Pubitemid 38509178)
27. Mustafa T, Lee JH, Chai SY, Albiston AL, McDowall SG, and Mendelsohn FA (2001) Bioactive angiotensin peptides: focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst 2:205-210. (Pubitemid 33685893)
28. Nagahara AH and Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10:209-219.
29. Pederson ES, Krishnan R, Harding JW, and Wright JW (2001) A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept 102:147-156. (Pubitemid 33135576)
30. Shou WZ, Magis L, Li AC, Naidong W, and Bryant MS (2005) A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. J Mass Spectrom 40:1347-1356. (Pubitemid 41552475)
31. Stubley-Weatherly L, Harding JW, and Wright JW (1996) Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory in rats. Brain Res 716:29-38. (Pubitemid 26156598)
32. von Bohlen und Halbach O (2003) Angiotensin IV in the central nervous system. Cell Tissue Res 311:1-9.
33. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng H-YM, Marks D, Obrietan K, Soderling TR, and Goodman RH, et al. (2008) An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci USA 105:9093-9098.
34. Wayman GA, Impey S, Marks D, Saneyoshi T, Grant WF, Derkach V, and Soderling TR (2006) Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 50:897-909. (Pubitemid 43850689)
35. Wright JW, Clemens JA, Panetta JA, Smalstig EB, Weatherly LA, Kramár EA, Pederson ES, Mungall BH, and Harding JW (1996) Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 717:1-11. (Pubitemid 26155069)
36. Wright JW and Harding JW (2010) The brain RAS and Alzheimer's disease. Exp Neurol 223:326-333.
37. Wright JW, Morseth SL, Abhold RH, and Harding JW (1985) Pressor action and dipsogenicity induced by angiotensin II and III in rats. Am J Physiol 249: R514-R521. (Pubitemid 16204004)
38. Wright JW, Stubley L, Pederson ES, Kramár EA, Hanesworth JM, and Harding JW (1999) Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19:3952-3961. (Pubitemid 29222269)
39. Wright JW, Wilson WL, Wakeling V, Boydstun AS, Jensen A, Kawas LH, and Harding JW (2012) The angiotensin IV analogue and hepatocyte growth factor/c-Met antagonist, divalinal-AngIV, attenuates the acquisition of methamphetamine- dependent condition place preference in rats. Brain Sci 2: 298 -318.
40. Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, and Harding JW (2010) The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther 333:161-173.
41. Yasumatsu N, Matsuzaki M, Miyazaki T, Noguchi J, and Kasai H (2008) Principles of long-term dynamics of dendritic spines. J Neurosci 28:13592-13608.
42. Yuste R and Bonhoeffer T (2001) Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu Rev Neurosci 24:1071-1089. (Pubitemid 32695254)
43. Zeng Y, Lv F, Li L, Yu H, Dong M, and Fu Q (2012) 7,8-dihydroxyflavone rescues spatial memory and synaptic plasticity in cognitively impaired aged rats. J Neurochem. 122:800-11.